Akero Therapeutics Inc
AKRO45.220USD
-0.980-2.12%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.61BMarket Cap
LossP/E TTM
More Details of Akero Therapeutics Inc Company
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Company Info
Ticker SymbolAKRO
Company nameAkero Therapeutics Inc
IPO dateJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Number of employees63
Security typeOrdinary Share
Fiscal year-endJun 20
Address601 Gateway Boulevard, Suite 350
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16504876488
Websitehttps://akerotx.com/
Ticker SymbolAKRO
IPO dateJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
259.33K
-6.10%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
191.89K
-0.30%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
24.95K
-2.57%
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
9.40K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott A. Gangloff
Mr. Scott A. Gangloff
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Judy Chou, Ph.D.
Dr. Judy Chou, Ph.D.
Independent Director
Independent Director
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
259.33K
-6.10%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
191.89K
-0.30%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
24.95K
-2.57%
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
9.40K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 3
Updated: Wed, Sep 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
8.42%
General Atlantic LLC
7.17%
RTW Investments L.P.
6.85%
BlackRock Institutional Trust Company, N.A.
6.33%
The Vanguard Group, Inc.
5.65%
Other
65.58%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
8.42%
General Atlantic LLC
7.17%
RTW Investments L.P.
6.85%
BlackRock Institutional Trust Company, N.A.
6.33%
The Vanguard Group, Inc.
5.65%
Other
65.58%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
45.93%
Investment Advisor
32.77%
Hedge Fund
20.82%
Private Equity
9.34%
Research Firm
3.22%
Venture Capital
3.02%
Individual Investor
1.22%
Foundation
0.41%
Pension Fund
0.31%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
491
87.62M
109.91%
-627.50K
2025Q1
495
89.01M
111.79%
+1.41M
2024Q4
453
76.50M
96.29%
-13.73M
2024Q3
445
77.37M
111.97%
-14.20M
2024Q2
428
76.12M
110.88%
-16.59M
2024Q1
421
77.80M
117.45%
+1.74M
2023Q4
401
63.49M
113.86%
-5.60M
2023Q3
387
61.40M
112.62%
-2.96M
2023Q2
363
60.44M
111.44%
+4.13M
2023Q1
350
52.43M
112.99%
-8.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
7.07M
8.87%
+1.03M
+17.14%
Mar 31, 2025
General Atlantic LLC
5.23M
6.57%
--
--
Mar 31, 2025
RTW Investments L.P.
7.42M
9.31%
+559.52K
+8.16%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.48M
6.88%
+346.72K
+6.75%
Mar 31, 2025
The Vanguard Group, Inc.
4.22M
5.29%
+526.23K
+14.25%
Mar 31, 2025
T. Rowe Price Associates, Inc.
4.73M
5.94%
+490.10K
+11.55%
Mar 31, 2025
Wellington Management Company, LLP
5.94M
7.45%
-1.44M
-19.53%
Mar 31, 2025
Deep Track Capital LP
3.21M
4.03%
+1.72M
+115.45%
Mar 31, 2025
State Street Global Advisors (US)
2.49M
3.13%
+158.80K
+6.80%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Global X Russell 2000 Covered Call ETF
0%
Fidelity Small-Mid Multifactor ETF
0%
Humankind US Stock ETF
0%
Eventide US Market ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Equity ETF
0%
Simplify Health Care ETF
0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Fidelity Small-Mid Multifactor ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
Eventide US Market ETF
Proportion0%
Alger Mid Cap 40 ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
Simplify Health Care ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
